Krystal Biotech (NASDAQ: KRYS) 30-day option implied volatility is at 131; compared to its 52-week range of 45 to 325 after topline data expected from the pivotal GEM-3 trial evaluating B-VEC. Call put ratio 1 call to 2.9 puts as shares rally 119%.